Citations (60)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Frank Nobels, Dirk D’Hooge & Laurent Crenier. (2012) Switching to biphasic insulin aspart 30/50/70 from biphasic human insulin 30/50 in patients with type 2 diabetes in normal clinical practice: observational study results. Current Medical Research and Opinion 28:6, pages 1017-1026.
Read now
Read now
Carol Wysham, Cameron Lush, Bei Zhang, Holly Maier & Ken Wilhelm. (2008) Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes. Current Medical Research and Opinion 24:1, pages 79-85.
Read now
Read now
Catherine A Schnabel, Matthew Wintle & Orville Kolterman. (2006) Metabolic Effects of the Incretin Mimetic Exenatide in the Treatment of Type 2 Diabetes. Vascular Health and Risk Management 2:1, pages 69-77.
Read now
Read now
David Owens & Jiten Vora. (2006) Insulin aspart: a review. Expert Opinion on Drug Metabolism & Toxicology 2:5, pages 793-804.
Read now
Read now
Samuel Edwin Fineberg. (2006) Diabetes therapy trials with inhaled insulin. Expert Opinion on Investigational Drugs 15:7, pages 743-762.
Read now
Read now
Articles from other publishers (55)
Yuqin Gan, Mengjie Chen, Laixi Kong, Juan Wu, Ying Pu, Xiaoxia Wang, Jian Zhou, Xinxin Fan, Zhenzhen Xiong & Hong Qi. (2023) A study of factors influencing long-term glycemic variability in patients with type 2 diabetes: a structural equation modeling approach. Frontiers in Endocrinology 14.
Crossref
Crossref
Xuelin Yao, Jie Zhang, Xiaoqian Zhang, Tian Jiang, Yi Zhang, Fang Dai, Honglin Hu & Qiu Zhang. (2023) Age at diagnosis, diabetes duration and the risk of cardiovascular disease in patients with diabetes mellitus: a cross-sectional study. Frontiers in Endocrinology 14.
Crossref
Crossref
Tzu-En Wu, Yu-Wen Su & Harn-Shen Chen. (2022) Mean HbA1c and HbA1c variability are associated with differing diabetes-related complications in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 192, pages 110069.
Crossref
Crossref
Rahmatullah .Muhammad Qutubuddin, Rabia Abdul Rahman, Erum Ghafoor & Musarrat Riaz. (2021) Assessment of Factors Associated With Non-Compliance to Self-Management Practices in People With Type 2 Diabetes. Cureus.
Crossref
Crossref
Jiaqi Hu, Huichun Hsu, Xiaodan Yuan, Kezheng Lou, Cunyi Hsue, Joshua D. Miller, Juming Lu, Yaujiunn Lee & Qingqing Lou. (2020) HbA1c variability as an independent predictor of diabetes retinopathy in patients with type 2 diabetes. Journal of Endocrinological Investigation 44:6, pages 1229-1236.
Crossref
Crossref
Abdul Hanif Khan Yusof Khan, Nor Fadhlina Zakaria, Muhammad Adil Zainal Abidin & Nor Azmi Kamaruddin. (2021) Prevalence of glycemic variability and factors associated with the glycemic arrays among end-stage kidney disease patients on chronic hemodialysis. Medicine 100:30, pages e26729.
Crossref
Crossref
Chen-Yi Yang, Pei-Fang Su, Jo-Ying Hung, Huang-Tz Ou & Shihchen Kuo. (2020) Comparative predictive ability of visit-to-visit HbA1c variability measures for microvascular disease risk in type 2 diabetes. Cardiovascular Diabetology 19:1.
Crossref
Crossref
Qian Zhao, Fan Zhou, Yusheng Zhang, Xiaoyan Zhou & Changjiang Ying. (2019) Fasting plasma glucose variability levels and risk of adverse outcomes among patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice 148, pages 23-31.
Crossref
Crossref
Emanuela Orsi, Anna Solini, Enzo Bonora, Cecilia Fondelli, Roberto Trevisan, Monica Vedovato, Franco Cavalot, Gabriella Gruden, Susanna Morano, Antonio Nicolucci, Giuseppe Penno & Giuseppe Pugliese. (2018) Haemoglobin A1c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 20:8, pages 1885-1893.
Crossref
Crossref
Dragana Lovre, Sulay Shah, Aanu Sihota & Vivian A. Fonseca. (2018) Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients. Endocrinology and Metabolism Clinics of North America 47:1, pages 237-257.
Crossref
Crossref
Valencia Foo, Joanne Quah, Gemmy Cheung, Ngiap Chun Tan, Kyi Lin Ma Zar, Choi Mun Chan, Ecosse Lamoureux, Wong Tien Yin, Gavin Tan & Charumathi Sabanayagam. (2016) HbA1c, systolic blood pressure variability and diabetic retinopathy in Asian type 2 diabetics. Journal of Diabetes 9:2, pages 200-207.
Crossref
Crossref
Yue-ping Jin, Xiao-fei Su, Guo-ping Yin, Xiao-hua Xu, Ji-zhuang Lou, Jian-jun Chen, Yue Zhou, Jie Lan, Bing Jiang, Zheng Li, Kok-Onn Lee, Lei Ye & Jian-hua Ma. (2015) Blood glucose fluctuations in hemodialysis patients with end stage diabetic nephropathy. Journal of Diabetes and its Complications 29:3, pages 395-399.
Crossref
Crossref
Cherng-Ru Hsu, Yu-Tsung Chen & Wayne H.-H. Sheu. (2015) Glycemic variability and diabetes retinopathy: A missing link. Journal of Diabetes and its Complications 29:2, pages 302-306.
Crossref
Crossref
S. Del Prato, R. Camisasca, C. Wilson & P. Fleck. (2014) Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes, Obesity and Metabolism 16:12, pages 1239-1246.
Crossref
Crossref
Giuseppe Penno, Anna Solini, Giacomo Zoppini, Emanuela Orsi, Cecilia Fondelli, Gianpaolo Zerbini, Susanna Morano, Franco Cavalot, Olga Lamacchia, Roberto Trevisan, Monica Vedovato & Giuseppe Pugliese. (2013) Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicenter Study. Cardiovascular Diabetology 12:1.
Crossref
Crossref
Giuseppe Penno, Anna Solini, Enzo Bonora, Cecilia Fondelli, Emanuela Orsi, Gianpaolo Zerbini, Susanna Morano, Franco Cavalot, Olga Lamacchia, Luigi Laviola, Antonio Nicolucci & Giuseppe Pugliese. (2013) HbA1c Variability as an Independent Correlate of Nephropathy, but Not Retinopathy, in Patients With Type 2 Diabetes. Diabetes Care 36:8, pages 2301-2310.
Crossref
Crossref
E. S. Kilpatrick. (2012) The rise and fall of HbA1c as a risk marker for diabetes complications. Diabetologia 55:8, pages 2089-2091.
Crossref
Crossref
Andreas Pfützner, Markolf Hanefeld, Lida A. Dekordi, Jürgen Müller, Iris Kleine, Winfried Fuchs & Thomas Forst. (2011) Effect of Pioglitazone and Ramipril on Biomarkers of Low-Grade Inflammation and Vascular Function in Nondiabetic Patients with Increased Cardiovascular Risk and an Activated Inflammation: Results from the PIOace Study. Journal of Diabetes Science and Technology 5:4, pages 989-998.
Crossref
Crossref
Mark E. Williams, Eduardo Lacson, Weiling Wang, J. Michael Lazarus & Raymond Hakim. (2010) Glycemic Control and Extended Hemodialysis Survival in Patients with Diabetes Mellitus. Clinical Journal of the American Society of Nephrology 5:9, pages 1595-1601.
Crossref
Crossref
E. S. Kilpatrick, A. S. Rigby & S. L. Atkin. (2010) For debate.Glucose variability and diabetes complication risk: we need to know the answer. Diabetic Medicine 27:8, pages 868-871.
Crossref
Crossref
Chidambarann SudhakaranMaryam FathimaRanjit Mohan AnjanaRanjit Unnikrishnan IViswanathan Mohan. (2010) Effectiveness of Exenatide in Asian Indians in a Clinical Care Setting. Diabetes Technology & Therapeutics 12:8, pages 613-618.
Crossref
Crossref
Chul Sik KimSo Young ParkSung Hoon YuJun Goo KangOhk Hyun RyuSeong Jin LeeEun Gyung HongHyeon Kyu KimDoo-Man KimJae Myung YooSung Hee IhmMoon Gi ChoiHyung Joon Yoo. (2010) Is A1C Variability an Independent Predictor for the Progression of Atherosclerosis in Type 2 Diabetic Patients?. Korean Diabetes Journal 34:3, pages 174.
Crossref
Crossref
R. Kawamori, Y. Iwamoto, T. Kadowaki, M. Iwasaki, S.-W. Kim, J.-T. Woo, S.-H. Baik & K.-H. Yoon. (2009) Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 11:9, pages 900-909.
Crossref
Crossref
G. Zoppini, G. Verlato, G. Targher, S. Casati, E. Gusson, V. Biasi, F. Perrone, E. Bonora & M. Muggeo. (2009) Is fasting glucose variability a risk factor for retinopathy in people with type 2 diabetes?. Nutrition, Metabolism and Cardiovascular Diseases 19:5, pages 334-339.
Crossref
Crossref
Marcus HompeschAlexa KollmeierKlaus RaveLutz HeinemannMichael MitnickSimon DaviesThomas Strack. (2009) Glycemic Exposure Is Affected Favorably by Inhaled Human Insulin (Exubera) as Compared with Subcutaneous Insulin Glargine (Lantus) in Patients with Type 2 Diabetes. Diabetes Technology & Therapeutics 11:5, pages 307-313.
Crossref
Crossref
Nadia M. Hamdy, Salwa M. Suwailem & Hala O. El-Mesallamy. (2009) Influence of vitamin E supplementation on endothelial complications in type 2 diabetes mellitus patients who underwent coronary artery bypass graft. Journal of Diabetes and its Complications 23:3, pages 167-173.
Crossref
Crossref
Ian W Campbell. (2009) Review: Durable glycaemia — the promised land. The British Journal of Diabetes & Vascular Disease 9:2, pages 53-63.
Crossref
Crossref
Derek D. Mafong & Robert R. Henry. (2009) The role of incretins in cardiovascular control. Current Hypertension Reports 11:1, pages 18-22.
Crossref
Crossref
R. H. A. Becker, A. D. Frick, L. Teichert, L. Nosek, L. Heinemann & K. Rave. (2009) Dose-response relationship of insulin glulisine in subjects with type 1 diabetes. Diabetes, Obesity and Metabolism 11:1, pages 60-68.
Crossref
Crossref
T. HeiseU. EckersK. KancJ.N. NielsenL. Nosek. (2008) The Pharmacokinetic and Pharmacodynamic Properties of Different Formulations of Biphasic Insulin Aspart: A Randomized, Glucose Clamp, Crossover Study. Diabetes Technology & Therapeutics 10:6, pages 479-485.
Crossref
Crossref
P. Augstein, S. Berg, P. Heinke, S. Altmann, E. Salzsieder, H. U. Demuth & E. J. Freyse. (2008) Efficacy of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide (P32/98) in fatty Zucker rats with incipient and manifest impaired glucose tolerance. Diabetes, Obesity and Metabolism 10:10, pages 850-861.
Crossref
Crossref
Richard M. Bergenstal, Mary Johnson, Margaret A. Powers, Alan Wynne, Aleksandra Vlajnic, Priscilla Hollander & Marc Rendell. (2008) Adjust to Target in Type 2 Diabetes. Diabetes Care 31:7, pages 1305-1310.
Crossref
Crossref
Mario Maioli, Giovanni Mario Pes, Manuela Sanna, Sara Cherchi, Mariella Dettori, Elena Manca & Giovanni Antonio Farris. (2008) Sourdough-leavened bread improves postprandial glucose and insulin plasma levels in subjects with impaired glucose tolerance. Acta Diabetologica 45:2, pages 91-96.
Crossref
Crossref
Daniel Magnoni, Carlette H.F.C. Rouws, Mirian Lansink, Katrien M.J. van Laere & Antonio C. Campos. (2008) Long-term use of a diabetes-specific oral nutritional supplement results in a low-postprandial glucose response in diabetes patients. Diabetes Research and Clinical Practice 80:1, pages 75-82.
Crossref
Crossref
Klaus Rave, Tim Heise, Lutz Heinemann & Anders H. Boss. (2008) Inhaled Technosphere® Insulin in Comparison to Subcutaneous Regular Human Insulin: Time Action Profile and Variability in Subjects with Type 2 Diabetes. Journal of Diabetes Science and Technology 2:2, pages 205-212.
Crossref
Crossref
Cees J. Tack, Vladimir Christov, Bastiaan E. de Galan, Karl-Michael Derwahl, Gerhard Klausmann, Terezie Pelikánová, Jindra Perušičová, Anders H. Boss, Nikhil Amin, David Kramer, Richard Petrucci, Wen Yu & Wen Yu. (2008) Randomized Forced Titration to Different Doses of Technosphere® Insulin Demonstrates Reduction in Postprandial Glucose Excursions and Hemoglobin A1c in Patients with Type 2 Diabetes. Journal of Diabetes Science and Technology 2:1, pages 47-57.
Crossref
Crossref
Derek D. Mafong & Robert R. Henry. (2008) Exenatide as a treatment for diabetes and obesity: Implications for cardiovascular risk reduction. Current Atherosclerosis Reports 10:1, pages 55-60.
Crossref
Crossref
Simon Heller. (2007) Targeting acute hyperglycaemia in clinical practice. Diabetes Research and Clinical Practice 78:3, pages S40-S46.
Crossref
Crossref
Matthew Riddle, Juan Frias, Bei Zhang, Holly Maier, Carl Brown, Karen Lutz & Orville Kolterman. (2007) Pramlintide Improved Glycemic Control and Reduced Weight in Patients With Type 2 Diabetes Using Basal Insulin. Diabetes Care 30:11, pages 2794-2799.
Crossref
Crossref
Hubert Kolb, Berthold Schneider, Lutz Heinemann, Volker Lodwig, Werner A. Scherbaum & Stephan Martin. (2016) Altered Disease Course after Initiation of Self-Monitoring of Blood Glucose in Noninsulin-Treated Type 2 Diabetes (ROSSO 3). Journal of Diabetes Science and Technology 1:4, pages 487-495.
Crossref
Crossref
M. Rambod & B. Broumand. (2007) Glycosylated hemoglobin, glycemic control, and mortality in hemodialyzed diabetic patients. Kidney International 71:10, pages 1078.
Crossref
Crossref
Belinda P. Childs, Nicole C. Kesty, Eric Klein, Richard Rubin & Allison Wick. (2007) Considering Pramlintide Therapy for Postprandial Blood Glucose Control. Diabetes Spectrum 20:2, pages 108-114.
Crossref
Crossref
Reinhard H.A. Becker. (2007) Insulin Glulisine Complementing Basal Insulins: A Review of Structure and Activity. Diabetes Technology & Therapeutics 9:1, pages 109-121.
Crossref
Crossref
S. F. E. Praet, H. M. M. De Feyter, R. A. M. Jonkers, K. Nicolay, C. van Pul, H. Kuipers, L. J. C. van Loon & J. J. Prompers. (2006) 31P MR spectroscopy and in vitro markers of oxidative capacity in type 2 diabetes patients. Magnetic Resonance Materials in Physics, Biology and Medicine 19:6, pages 321-331.
Crossref
Crossref
Marjorie Cypress & Donna Tomky. (2006) Microvascular Complications of Diabetes. Nursing Clinics of North America 41:4, pages 719-736.
Crossref
Crossref
G Lazarevic, S Antic, T Cvetkovic, P Vlahovic, I Tasic & V Stefanovic. (2006) A physical activity programme and its effects on insulin resistance and oxidative defense in obese male patients with type 2 diabetes mellitus. Diabetes & Metabolism 32:6, pages 583-590.
Crossref
Crossref
Paolo Di Bartolo, Francesca Pellicano, Antonio Scaramuzza, Tiziano Fabbri, Piero Melandri, Valerio Miselli, T. Casetti & Francesco Cannatà. (2006) Aspart and lispro insulin, is there any difference when used with an insulin pump treatment?. Diabetes Research and Clinical Practice 74, pages S119-S122.
Crossref
Crossref
U. SMITH, M. LAAKSO, B. ELIASSON, C. WESSLAU, J. BORÉN, O. WIKLUND & S. ATTVALL. (2006) Pathogenesis and treatment of diabetic vascular disease ? illustrated by two cases. Journal of Internal Medicine 260:5, pages 409-420.
Crossref
Crossref
Steve Edelman, Satish Garg, Juan Frias, David Maggs, Yan Wang, Bei Zhang, Susan Strobel, Karen Lutz & Orville Kolterman. (2006) A Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes. Diabetes Care 29:10, pages 2189-2195.
Crossref
Crossref
M. Hausmann, S. Dellweg, C. Osborn, L. Heinemann, A. Buchwald, R. Rosskamp, P. Genova & T. Heise. (2006) Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study. Diabetes, Obesity and Metabolism 8:5, pages 574-580.
Crossref
Crossref
Klaus Rave, Oliver Klein, Annke D. Frick & Reinhard H.A. Becker. (2006) Advantage of Premeal-Injected Insulin Glulisine Compared With Regular Human Insulin in Subjects With Type 1 Diabetes. Diabetes Care 29:8, pages 1812-1817.
Crossref
Crossref
Eric S. KilpatrickAlan S. RigbyStephen L. Atkin. (2006) The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes. Diabetes Care 29:7, pages 1486-1490.
Crossref
Crossref
S. Ristic, C. Collober-Maugeais, E. Pecher & F. Cressier. (2006) Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine 23:7, pages 757-762.
Crossref
Crossref
A J Krentz & D C Wheeler. (2006) New‐onset diabetes after transplantation. Practical Diabetes International 23:1, pages 34-42.
Crossref
Crossref
I. W. Campbell. (2005) Nateglinide - current and future role in the treatment of patients with type 2 diabetes mellitus. International Journal of Clinical Practice 59:10, pages 1218-1228.
Crossref
Crossref